-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NAoDRhoQI1H36wCwnktZs2VcwVU+xUCGhS4ZdGfxcfRTeTwx4lXVcgh3HOBLHs/x
 wXsHHJu2nOXMwRFW/DvWIA==

<SEC-DOCUMENT>0001193125-05-113915.txt : 20050524
<SEC-HEADER>0001193125-05-113915.hdr.sgml : 20050524
<ACCEPTANCE-DATETIME>20050524160150
ACCESSION NUMBER:		0001193125-05-113915
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20050524
DATE AS OF CHANGE:		20050524
EFFECTIVENESS DATE:		20050524

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OXIS INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-08092
		FILM NUMBER:		05854459

	BUSINESS ADDRESS:	
		STREET 1:		6040 N CUTTER CIRCLE STE 317
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97217
		BUSINESS PHONE:		5032833911

	MAIL ADDRESS:	
		STREET 1:		6040 N CUTTER CIRCLE STE 317
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97217

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ddefa14a.htm
<DESCRIPTION>DEFINITIVE ADDITIONAL MATERIALS
<TEXT>
<HTML><HEAD>
<TITLE>Definitive Additional Materials</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SCHEDULE 14A INFORMATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Proxy Statement Pursuant to Section 14(a) of </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>the Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;)
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Filed by the
Registrant&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#254;</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT
FACE="Times New Roman" SIZE="2">Filed by a Party other than the Registrant&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"> </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box: </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="48%"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Preliminary Proxy
Statement </FONT></P></TD>
<TD> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:4%; text-indent:-4%"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman"
SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential, for Use of the Commission Only </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="52%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(as</FONT></TD>
<TD WIDTH="2%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">permitted by Rule 14a-6(e)(2)) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman"
SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Definitive Proxy Statement </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT
FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;Definitive Additional Materials </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman"
SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Soliciting Material Pursuant to Section 240.14a-11(c) or Section 240.14a-12 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>&nbsp;&nbsp;&nbsp;&nbsp;Oxis International, Inc.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P><HR WIDTH="60%" SIZE="1" NOSHADE COLOR="#000000"> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Name of Registrant as Specified In Its Certificate) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><HR
WIDTH="60%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Payment of Filing Fee (Check the appropriate box):
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#254;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">No fee required. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Title of each class of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was
determined): </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Total fee paid: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Fee paid previously with preliminary materials. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amount Previously Paid: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form, Schedule or Registration Statement No.:&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filing Party:&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date Filed:&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g54439g87j39.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="3">Dear Shareholder, </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="3">As the new Chief Executive Officer of OXIS International, I would like to introduce myself
and thank you for your continued support. As an experienced diagnostic and pharmaceutical executive, with such organizations as Amarin Pharmaceuticals, Elan Pharmaceuticals, Athena Diagnostics, and Athena Neurosciences, I&#146;m very excited about
the technology assets of OXIS&#146; portfolio today. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="3">The Company has completed
the $6.5 million investment round announced late last year and has retired OXIS&#146; corporate debt. I would like to share with you the significant opportunities the Company will focus on moving forward &#151; in the areas of biomarker research,
clinical cardiac-predictor testing and the neutraceutical marketplace. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="3">Possible health issues associated with anti-inflammatory drugs such as Vioxx<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><SUP>&reg;<FONT FACE="Times New Roman" SIZE="3" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman"
SIZE="3" COLOR="#000000"></FONT></FONT> and Celebrex<FONT FACE="Times New Roman" SIZE="2" COLOR="#000000"><SUP>&reg;<FONT FACE="Times New Roman" SIZE="3" COLOR="#000000"></FONT></SUP><FONT FACE="Times New Roman" SIZE="3"
COLOR="#000000"></FONT></FONT> have made the front pages over the last few months. Such highly publicized concerns underscore the important role that biomarkers can play to help physicians make more informed decisions on timing, quantity, type of
drugs and treatment procedures involving inflammation. These developments place OXIS at the epicenter of a new age of biomarkers that can help physicians predict the early onset of disease as well as monitor therapeutic response. </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="3">At the same time, the benefits of antioxidants are becoming more obvious to both physicians
and patients. Powerful antioxidants, such as OXIS&#146; Ergothioneine, can provide safe and effective remedies for patients with oxidative-stress health concerns. Ergothioneine is one of the most powerful antioxidants available and promises to be a
compelling neutraceutical remedy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="3">Within this exciting market context, OXIS
will focus on five key areas to grow the Company&#146;s revenues: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="3">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="3">Accelerate revenue growth leveraging OXIS&#146; worldwide leadership in oxidative-stress research products. Our biomarker products are at the forefront in the study of oxidative
stress in cancer, cardiovascular, diabetes, HIV and inflammatory disease states. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="3">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="3">Use OXIS&#146; proprietary cardiac predictor tests to enter the clinical laboratory market. Ushering in &#147;a new era of heart disease detection&#148; according to <I>USA
Today</I> in 2003, OXIS&#146; MPO assay enables the prediction of early risk of cardiovascular diseases, according to an article by the Cleveland Clinic in the <I>New England Journal of Medicine</I>. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Corporate Headquarters </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6040 N. Cutter Circle, Suite 317 - Portland, OR 97217-3935 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">Telephone: 800-547-3686
&#150; Facsimile: 503-283-4058 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="3">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="3">Launch Ergothioneine as a neutraceutical supplement sold over-the-counter. OXIS has developed a proprietary method for commercially producing this powerful, naturally occurring
antioxidant. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="3">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="3">Acquire synergistic businesses or technologies that will increase revenues and accelerate the growth of the Company. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="3">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="3">Build a skilled management team that is strategically focused to commercialize scientific advances creating increased revenue streams. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="3">These strategies can offer tremendous advances to the markets we serve and build substantial
OXIS shareholder equity. I look forward to leading OXIS as we capitalize on the many opportunities ahead of us, and will keep you informed of our continued progress as we move forward. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="3">Sincerely, </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g54439g35v75.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="3">Steve Guillen </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="3"><I>Chief Executive
Officer</I> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="3">OXIS International, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1"></FONT><FONT FACE="ARIAL" SIZE="1" COLOR="#000000">Vioxx is a registered trademark of Merck; Celebrex is a registered trademark of Pfizer.</FONT><FONT
FACE="Times New Roman" SIZE="1" COLOR="#000000"> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>CAUTIONARY STATEMENT
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>The statements contained in this letter to OXIS
stockholders that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, statements regarding the
Company&#146;s expectations, objectives, anticipations, plans, hopes, beliefs, intentions or strategies regarding the future. Forward-looking statements include, without limitation, statements regarding: (a) the important role that biomarkers can
play to help physicians make more informed decisions on timing, quantity, type of drugs and treatment procedures involving inflammation; (b) OXIS being placed at the epicenter of a new age of biomarkers; (c) OXIS&#146; Ergothioneine providing a
safe, effective and compelling neutraceutical remedy for patients; (d) acceleration of revenue growth by leveraging OXIS&#146; worldwide leadership in oxidative-stress research products; (e) using OXIS&#146; proprietary cardiac predictor tests to
enter the clinical laboratory market and participating in a new era of heart disease detection; (f) launching Ergothioneine as a neutraceutical supplement sold over-the-counter; (g) acquiring synergistic businesses or technologies that will increase
revenues and accelerate the growth of the Company; (h) building a skilled management team that is strategically focused to commercialize scientific advances and create increased revenue streams; and (i) the Company&#146;s strategies offering
tremendous advances to the markets served and building substantial OXIS shareholder equity. All forward-looking statements included in this document are based on information available to the Company on the date hereof, and the Company assumes no
obligation to update any such forward-looking statements. Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause
actual results to differ materially from such forward-looking statements. These include, among others, the cautionary statements in the &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results
of Operations&#148; sections of our enclosed Form 10-KSB filed with the Securities and Exchange Commission on February 25, 2005. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">SKU 2710-CL-05 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g54439g35v75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g54439g35v75.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0IN4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````)````)H````&`&<`,P`U
M`'8`-P`U`````0`````````````````````````!``````````````":````
M)``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!](````!````<````!H`
M``%0```B(```![8`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``:`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5))))2E4R.J8&-GXG3K[0S+S_4^RU0XE_I-]6[W-:6,V5_Z1-U+J
MF)TVIK[RY]MA+<?&K&ZZYX_P6/5_A'_^!5?SM]E5/Z1<UT[#OZIAV?7'J63^
MS,ZZ@_9+&!EE>'A,<ZWV_:&/JR'Y5?Z;(S=G\R_]6]"K^<2GK77T,N90ZQK;
MK0YU=9<`YP9M]1S&?2>VO>S?_71%P/3:^NOZOB]9S>H8]/4NJ568G2<7*Q7O
ML=B5G[8;KF8F3CU8N5<S]-D?SGI?H:?T=GZ!==T[/W&S&R\JB[+JM]%WH,=4
MW?L^T?9VBZV_U+V4?IK&LM_F_P#!I*=!1LLKJK=;:X,KK!<][C#0T"7.<X_1
M:U9_2NNXG5<O/Q\0.<SIUHH??H:WOC=8RIS2?YEWLL6=]<<_'?7B_5OUVT9'
M7;!C/<7;2S&/],>USF65^K>S]1Q:W_SN3E5[/YMZ2F?U$ZD[JGU:HS;+3;9;
M;D.?N<7.9NONLKI?N]WZ*E]3&?\`![/\&KW3.JV=1S<X55_Y/Q7-HIR=?TUS
M=_VWTOWJ,=_I8_J?]R&9/^C6-];.E]-?%%`LQ\[J;358^FVVJEE%+0,GJ.;C
MT748US<'%VU5?:&/]2Y^%B6?H5L59G1^DM_9-;O0KZ=AC(>-KBRK&9-3'VWQ
MZ>YWI6^US_6L]*ZQ)3=KR\6V^[&JN8^_&V^O4UP+F;QOJ]5@]U?J,]S-RKT]
M:Z7?1F9%62QU'3K+*LRW4-K?4UMM[7.(]WI5O]^Q<]U/K]V7TO%'U;Q'4]6^
MLGOI=8T5OKH:&U/ZGEOI];8QF-Z/V9^[U/TM'LW_`*!4K>@TY=&)]1>F7C]G
MX&V_ZP9#='OEWJ5XGM+MM^=>VVY_O_5::6?\3:E.I]3NH=3ZYDY_7[K'LZ5D
MN;3TK%.@%51=ZF2YC?\`"76'^O['U_S-=*ZA<1B?6TT_:NK@BKZMX]3L7HO3
MZJP+,IU`W7YE6N^O%QJZ+&,_P%>-^FR/1]!=5T6WJ-_2<6_JC&5YUM;;,BJM
MI8UCG^_T=ECK'[JMWIO]_P!-)3__T.^LZWU"JU]1Z)G6;7N:VRIV*YCVAQ:R
MUKK,RE[?49[]EM=;V((O^MV>S:W$Q.D5NW!SLBPY=L?F_JV-]GQF_P#L?<MU
M))3YE@XW4K<*CI6-31U+/ZCBBNSJ+\@MOJZ?4X4Y>!DL?1D?87;_`%.F,=B?
MTC)];.]+[51D+;ZOTGKMMO2W=2K.=@5WSD=(Z:&LQFLK98_#KN&2^I^=^MMQ
M?TEK\7!9Z/Z3#6QT'^G]7_Y/_I7_`&A_G>/^]3_NW_YFMI)3QMU?UI^U=2ZI
MDXCJKJJK&T64/98X8K&C(KPNETM;<]V?G9#?UW*RJ&;-F/\`9Z<CT_T=?%^J
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MZS7_`#N3^ER?M'5I)*>;I^J.51U&S+;U:][,JJNK,-C0<AS:W7V>EB9=3J:^
MG8UGVGW4X>)6]GH^I1=3=^D17_4[!^TVV8^3DXF)DLJ9DX..YK*K&TSZ;-_I
MG)IK>U]GVAF-D4^OO_2?GK?224XF%]3^BXF'=AN;;E57TG%)R;7V.;C'Z.%C
MOD?9\:MNWV4;/YNM]OJ6_I$]/U/Z#3=3>VJY]F,YME/JY63:&N:=S"VN_(LK
M^E_)6TDDI__9.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``
M:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H
M`&\`<``@`#8`+@`P`````0`X0DE-!`8```````<`"``!``$!`/_N``Y!9&]B
M90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("
M`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__``!$(`"0`F@,!$0`"$0$#$0'_W0`$`!3_Q`!T```!!0$``P$`
M````````````!@<("0H%`0(#!`$!`````````````````````!```00"`@$#
M!`$"`PD!````!0,$!@<""`$)`!(3%!$5%A<8(2(U-U=!(T-C)"5E)C8X$0$`
M````````````````````_]H`#`,!``(1`Q$`/P#?QX!X!X!X!X!X!X!X!X!X
M!X%/?2M?<MV;UZV3NN0VB=M:-3/L0WB7IXN;/D9&C':0'W68&5C#(T^)++9(
M0T#'VF/VILCPFV:LU<$T\,<<?IX$^]M=F:]TWUMN39VTL23B$TS!S$R*"@F+
M160R-PP1]`B*1MN^<LVCJ1RHPJ@/8IJ*IX9NG&'&66./UYX![(N7>GXS'3Q(
M$2BQ$V"$%W\8,9-,R\<>DA[=XZ!%<V"[ICF2$+K9-U^455$N54\O1EEC].>0
M[O@'@5H]KF_8OKTU,EEIC%XTZN:5IDH;0D9E2G/V(O8'V(F=<'9(BD^'.<H7
M`(V)>&BW."Z.:R#3%HEG\IVWPS!9]72^T1'0S7B1[G2-_*=CYT!E=ESL@6$,
M(^88#+0L286'7,4-1X6FF.CIN#5?)@H5X/1Y438NAZB'"JO"?NYA/OP#P/_0
MW\>`>`>`>!1AW>[`VLM4\%Z^M1@ZMA[?;QR<3!$X;'I.UCYB!:U,RK1W?EJR
M\VFT*D*[A+R'MUXWA(N6^*C%T7R<,<LWK5-+(.A179UUMZ2:^5'JK=&[L?9V
M!JI2T$I.<G+=AMIU6?E\CI:&!8+)#K1A944$KDW)TR%SS13;N7W*BJ^*6"RV
M?TRR!E.C[MJYWHJ"^;YV@V7UAB,BL;8>8&:-UD'VY536>Z_Z[A!`*&1`).@7
M)0?.D2LGD45,%?E&T,52'O9/6N*#)R@U0"_^)3N#SYDY)02912:CF;KX+Q_$
MI"(D;)H]X237Y9N70=X\00=<(+89^WEEQGZ,N.?I].>/`5?@'@5N=MVQ\LUA
MT"ON95<V($[VGX870&N``*C\N1']@M@#+&IJJ:QT=QSPH3*"9)*DROL8<999
M-QZO/IYXQYX\"O\`U'T\W&Z5H,XI/5BH\M^M3I.(A$H:P)C:48IZZ*0O=G!(
MA$KI-@LK7*OXI-ZFO:7AE98B,0+#W,3)NGR*2#MNOBKP'F@%=H.TW<R32+;F
MNZ^J+4GKSM.,YPS7^N;"(6T.L7>`")&'UW=LVMB!B47LE/5M-^@X3&AAB04;
M+BO#99P1>!%%L`T1>!#B(N3NHU6;271MKL3S+(,A;MW[`(2$\TX9@:)U_P"<
MVV4'JL-\5I@^*,(?$H^FY5Y]E1RX,$7*2/O8^SFH%-O5U,KAVRVYW([=-AIC
M.:PUXAT+EVMU#59/"J4<@]<5_"I$VG%J'2XC!!L,1.5_C'&@R6%%W3[%.:HR
M,>FMPS#M<U`@IIZ^-]\G8I:79#;R;J&]96D4C>UUK^'E+MBVB5JXUD2#6&[)
M21`XT9(-8R7E(T=-IFJNG[#AL/CH)?/-$6_S<!J(U'WJUCWDK^R[6UJL1&>5
MK5-LS*F)1-U!A(%&UY;!`D;D9Y['R1MLQ0/1'[)+&3EN7;\Y,7*2G.2:G/&&
M7T"2L*FL/LF'Q>P:]E,>G$$FX`3*H=,HD8'R&+RJ,GF*),)((\=%.'0PP&+#
MG*:[9RW44162SQRQRYXYXY\!3^!__]'?QX!X"'GUE0&K!0@Y8LM"0T.>F4)K
MP,1//4V+0C-[(E(J$P2,M55/[5"TIEAMHP:)_P#$<+XX_P!/K]?`KMV7WYE;
MNP9#J1H)$0=^[>#UL1D]E$@Y*I:Q:BME6J+]W*=FK&"IJX-I`S$*\KC(4+S6
MD)=QQ@FKBR;Y9.>`A_T4ZLY@`>QW858]GR78.U]T9Z]3C6Q5C-5F4PLB@*O+
M%8_$[#8A'.*8^LH#<\@:O9+&HJ'3;!0<&YC3+!/-9FJX5#D[!<BN[W8XQIE#
M#CHMUD:K38,_W>L2)%LV@O:B_HPY'R6(:C028!7JF3VO(`\^(7GC]EDBX^:F
MU8M5T%L<'7`*O6,?J-MULSO,_=:$Z"IZ/:AR4%3=<[''*"K)206)=<&`\&-D
MWZ1P]&\(LTJ^HWZK4'@];)<)_.&N5?F+)_[IJ'2IWMRTTK*C[*N^.TKG2ND(
MV_9!4VODGJ:M4L7MY#*Y9<\['[1-*GA8$1C%=>ZT,MG"#H[EPY=9L@KATX32
M66;,.`;G8KL.LG9GLYU9T<Z\['-'P%,S*JKTW5L6M68&5U*6J@V=`2-U6,IL
MK!$B)$#7-3,"B_H'.\7Q0\;",T?6BB5Q2#11SSQCQSEESQQQQQSSSSSS]...
M./Z\\\\\_P!..../`R<[8=BE?SGM"T4M2THB=-=:]+W1/:RHJ[P1(05JRU=R
MS+*-588OPLF[R7#2.I-<C5C(`(^4;YHY)'<I"99NG6`A%NJ%YO8)L58%/UK%
MJFUYR!/MP-J)-E3&LP@]RX6%`)"0;8J32[Y8Q8M"#_.N-?XBNK(S2F#=3!3)
M%JR^G*SY##,(MUMLAJUUU]=>Q.-2I'9O`^O&53G7]7,F;=EISL5LV-%Q.1R1
MHX//!R*T@MBXM@+35&%U6R3G#\G</>$\?2GRBF$?-_=X^Q2K-4-)];ZRB=<"
M^VCL$?80=NQ@0!XZ@.O(]L+1,6K;'X]*9+//ALZA$GAK5PZ(OS`I`CFNXXY>
M(HX(*@SO8>"N+MKVEK#JOURO1T-U]U2=5K;W9_L7'\HNL6(RG-WB[J:C(XV8
M1]6)\VR05BK^1OFR3;D0'>+L5UD,5!O+%4/W[OSF`32L=2.F3KT&X0C7B^[,
M`ZFV3>5<YD4XM7E)UF',S.[H#1DU25<-K&N)M#X&_;2<URH3'B7[_E`JX7+/
M5T4`].RQFC7@'3KHGZY<JEHF*6=#YM)=@$7Q7!Z%U[T@K=82O-3LW0-2IL>+
M,K1/RQTJ_P"23U1Y+_AD6KUUQ@0>.\0A]V$2(;7_`%NQK1O1":A];>O5>=UU
MI_.MW)G((Z$:[(6%<D@3RM(Q%IVHEDS>56'9XR:0VK/,&B>$C*(.`(/CAOR^
M<)AH'K[>;JWU>H^H*KB^[.JXNLZSK:%5Y7[9M>E7FW^,,A$:%QX$NZ9Q8KEE
MCBD'8(YN7&+1NWQR]6?/">/UXX"9'\C]?_\`6JKO\EOY'_\`W$<__/\`_K5_
MB'^5W_G/\._YO@?_TM7LV[&+!K&RK%KR:];'8:791*2F1T-LFG*KKJYZYM&,
M,$T^14I`E8E;'!F/J'U?7[(\PP9.4$^4\G'LJ9*HH`AL]_=X[.+)C-:NH[83
MD5\9;!]/=T+CIG42+#R>/IR11;1P$2V#M<ZRR173S]Y&/)8\Y\*)\\X98>KD
M()]GVK._VQ&DMDF-UMJJGJ^M8](:>F!.@])JY(QYD-X$7]59K"0V#M/>AB53
MF0-*E%L%BR)",1FMU,W;/Y+CGXO&3/P&#LC#LBI.B(;TF5+K%0!*S+/@YU$M
MLEKE??%9J3#6,3(62-V738->S*L)`8HVW+[!.7<77D#L_(EEIH9<DQV;C)OS
M@V"><_THWHNG6Z;`=G+%A,&IR#4I)1=;=:F@C:0QV'SUG"XRZRK:GK@VBF3J
M,W%8@4@S%,@KH5#T:Q&/,,\D5EE6^7/.00<K0]NU3'3K`=4NM?2R_P"NK3K"
M@*L'W9;5A4^PJT\;M&RWL&1V<(:U5Y9DMA4PFUQ!B\UELA0,%A>$=:J`DVK+
M[IDZ9^T'2VVC\JI3J_\`B2&B%-&-7(&6J2BM/M2'#UK,B[(_8TI9Q1/9;?EG
M5:<\:39E`2YQW/\`\!&/Y#^1E&"BDI^^%"?`MD%JG7)K:6`U"TG]A48RI\2R
MK=2A-2]89>Q$*EJ#TYC[9@.B<3M!9NO($GMQWVL$;R>P<UEG2B"JS$2O[RPM
M=PZ!=]1NH&>E6A=&55)J\CM=W2;`N[-V,'`!,('^_>]FF"4YL9FH[K_W(X3#
MQ,](%0@/ENLL@TCXYDU1RQ10PPQ!&6-K9V);+6+-ZMV!OS7>`Z-*6"F;9#=8
MHE:D8V4OBHLLE7'Z#N4_.I1(HM6$:<>A-E)2\2=/",O'*+HM\(XFIFFH#^;L
M:.UCMGHW;.F#",P"$1Z0T^4@%-Y)P"-/XQ24G%1=<-5,IA$3Y9-QL<RK5^DT
MS&_:_@.&"*'&+)9MGBFI@$<.MW7G:PLZQW7[(F0H?NI*ZRCU+`JI`DXP?@FM
MU70_%HVD[6&$HSD^&/)IL;/!"DTE+])XZX3;KB0J66*`;'W0@WGT:[6Q,5`G
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M$V(/A,\,V>..67(["L&=FI[)@\6`2B0SBQ9=,"\YL+F4!X0(;$&9P@0'.T1K
M9-1OS@BGCB%A1FGJDD4&#5?(*MKD[6D<;`&<>KLS"(R4@P%I%$4&\7:AHD]&
M+@!;:-MVJ2;#!!OABSP3QQ1XPXQXXX!KANEVG0;-54/J=K0)46PX364&T35K
M'-7#'GU8X*YM8JEDIACE_7CCGZ\<<^!)?P/_T]_'@'@-1?/Z=_2%P_R'_$OT
M'^KY[^[/SWX_X1^I_P`7*?L+\O\`E?\`3_C7XG\OYOK_`+?C>OZ^!7=U@?Q*
M]FQ_U'_)7^0/X[6/[1_G-^6_R]_3?V-S_'G[W^>?]\_4?XG[WV;V/[_NGW'[
M[_[5]\\"VCP#P/@X^-Z,?E>Q[?NI>GY'M^CWO<Q]CT^Y_;[ON_3T?[?5]/I_
97P/OX!X!X!X!X!X!X!X!X!X!X!X!X'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g54439g87j39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g54439g87j39.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0OF4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````0````-,````&`&<`.``W
M`&H`,P`Y`````0`````````````````````````!``````````````#3````
M0``````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````"4D````!````<````"(`
M``%0```LH```"2T`&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``B`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#U5,YS6-+G$-:T2YQT``[E.J/7->B]0_\`"UW_`)[>DI;]O]"Y_:6)
MK_P]?_DTOV]T+_RQQ?\`M^O_`,F@XWI>E6!6P>QGYC?W6_R5;K902!Z;->VT
M?W)*7QNI]-R[#7B9=.18!N+*K&O('&[:QSO;JJ?6>NMZ>^O$QZCE=0R!^AH!
MV@#_`$M]G^#J:N%/U[ZF[_&'^SZ,&FS'QK;\"NE@BTM.TVY;KYVMVNQ?6?[/
M3KQO^%_2K2^J^,WZQ]9S^I]3#<BAA!JI:2:'%Y>QGTMK\ZFJFG95;<RO&MW^
MK5C?X1)3L].?U;JU@L.6XX8)]3)H`JI>8]M?3/:^_(I:_P#G,^^WT;?^TE5G
MJ/MH74.H=0Z!F8XR,AV9TS*)876!HNJ(B7^I4UC;6>[?[V;UTBY#ZW$]2ZO@
M]&HU?.ZR-=OJ1J[_`(NAEEJ2F77LWK/1\ZC=FVNZ;>1+]E1L:&D>O7N]+Z7I
M_I*O_,%O9>;CX>+6QUME]M\MQVU[776D^[]"/:SVM_PCOT-3/YU4OK"*>HTN
MZ-0SU\T[;&AIAM$?0NR;/=Z;7?1;7_.W_F?Z1E#ZDWT6.OIN:?VA0T5A]A)<
M*&G:VBO=_-5X]HVOK9_P:2G7Z?@]6],V=1SK#8\DMHK%8;6"?:PVBK?>]K?I
M6>S^HLOI.5U7J'6LW%^W6?8<-Q:'!M6]QW&MC?4]+_@[5O\`4LL873\C+/\`
M@:W/`\2![1_G+&^I&)Z'23DO/Z3,L<Z3R0R:V_\`2;98DI6'U#)ZUU#)Q<?*
M=BX6##-U8:;[G2YALWV->VJG=7_@Z_41LS'ZOAY&$W&S;+L6_(97>RUK'6-;
MK8YU=[&,]CO3]-_J*EU7ZK95.4[J?0K33D27F@$-U<=UGHO/LVO=_P!I[OT/
M_%JW]6OK#;U,V8F97Z>90-SB`0'-!]-TL/\`-6,?_.,24__0]56)U_K726=-
MSL7[56_(=CW-]"L^I9/IN^E53ZEC?\U3'U5Z4_7-.1U`R71EY%MK)F?Z*ZS[
M'_[+HW4<3%Q.@YU.)2S'J&-=MKJ8&-'L?]%E8:DIY+.^NPP*K&8G3<K,OPZF
M&X%I8VN6M#/M.P6NJW;O\)Z?L7'=3_QB=:S2YF3:T4Q_0L,^E02/S<S+_29.
M53M_GZ*;:ZK?]*KO7\_K?6?U-CZJ^DT[&48[<FMK<@Q_2\VWU&/^S,C?]G_Z
MS_._IU3Z7]5<"WKM(ZE?37TJAILNL==4#DN:[:VG;4]WH,O_`-$QOZ#`_/\`
M724]+]4L#,ZYD=/S>MXU./B78]IQL>FEE!NKJ./LKO;4W<[I+76;\?$M?^LV
M?I[?U3TJETM>/9TSKV4>E6TY9R`+<OICK&LO8"99=5_P>ZQVWU?3_KHN)U#`
MR^MX3<.^F_TL;)W-I<'!C=V$UDAGT&^WV+F;^NV'-ZMU/%RC37<<JRRRFRMS
MCA]-J;T_#IH]6N]M+\WJ^;;?38DI[.W+ZW<TUXN"W'>1_/9-C2UOGZ6*ZU]O
M]7?2LO\`8_6,%US^GM&1GY1_6>J7N:';3!>S$QX>RO\`D>I[/^-]BP,3JO4K
M.H78UO5SC9F8PUF][2\>MA&OIY9A8[6^A6YN6W+ZEFXO^'Q\C&_[3^NHV_6'
MK5N*_,'5KV"_"R\VO';50&AME_V#ZO4L?Z#KF69-EF][W6?X+TTE/>]-PZ<+
M$%=-3JRXE]@>[?8]Y^G9?=+O5NL_TFY<V[I_4W?6&SJG2ZJ0:7AN30;F[M[F
MM=?5;Z;7MJ==4^JW_P`&6-E]?R.J75XC>J6-P\_T:;KMS<<M:^]S;-K6M_4W
M-Q>E=3^G?ZEWV^CU_1].JE&K^LW6,C!R,@Y+J,FO[/DX-1:S])5E/?E^ME[*
MF^KA8?2V^A;8ST]GH9MMOZQ]G]!*>DZ_1UKJF!]BQL5M0L+76OLM;PT[_3:&
M;_\`"-:J[Z<\U]+Z;AFC&ZATZ,A]-E@=-;*WXOJ[*OTOHY%EUM6_8N?/ULS*
MC^M=1M<<C#KRG5;&,#2X9'5G8;;F4M^S7MZ4S'Q?49]HOOLR*[*:Z[*_6JV/
MJAG?:\^[)SLFN_.LQL?#K<V#ZGV.NN_J5[7-:UFW]H=4LJ_ZRDIUCUO-?<_`
MIQ*SU%C=[Z'9-1#&G1MUC6%V3Z.O_<;WJ70NAGIIOR<FP9&?F.WWV@;6B27^
MG4W]S>]<C=UN<WJO4\7+^SUY!RKK;J7UO><3IM5?3<2FKU:[VTNR^K9=N10_
M9[_[:T_J_P!:NR7XMG5.JNJSJKG8.5T_TV['6AKJ*JKMK/T>3?;0_J-;ZW,_
M1?H?YA)3_]'U5)?*J22GZI^Y-]R^5TDE/U2._"9OR[<+Y7224_5)X/\`%+OV
MY7RLDDI^JD,_SP^A]%W/TN6_]#]]?+*22GZI'RY54_\`*8^C_,'Z7TOIM_F?
MY'_<K_T$7S`DDI^J!\NW"<=U\K))*?_9`#A"24T$(0``````50````$!````
M#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E
M`"``4`!H`&\`=`!O`',`:`!O`'``(``V`"X`,`````$`.$))300&```````'
M``@``0`!`0#_[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#
M`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`!``-,#`1$``A$!`Q$!_]T`
M!``;_\0`?@```@(#``,!`0``````````"0H'"``%!@(#!`L!`0$`````````
M````````````$```!@(!`P,"!`,%!@<````!`@,$!08'"!$`$@DA$Q0Q%4$B
M%A=183)Q(R08"H%24S0V5Z%BHB4U-S@1`0````````````````````#_V@`,
M`P$``A$#$0`_`'^.@SH,Z#.@SH,Z#.@SH,Z#.@^5Z]9QK-W(R+MLPCV#99X^
M?/5TFK-FT;)F6<.G3E<Q$6[=!(@F.<Y@*4H"(B`!T`S<G^4;$</;0QK@:GV[
M9?(RQSH(16.4B&@2KD.9)059XR;H56[8Y1%15-`S?M#T5Z")4MO]U;=F2M8!
M81^LF,\PVJ&DK6ABMV6_9,O%,J$9'*28V'+#BNR3.`QW&RB8)(QIWWM'DG+A
M--N13DQB!U>2]BO(QK?'A;<FX0P[F3'D<!G%CE\0KV^.L44P(/<J\<1\B[DT
MD&B"8")U"H+`F'YC!V\B`6,U3WRP[MQ#O&U)<GJN2&#-==UC>VN&Z<QPD@50
M)"-5;'[)R%35/VJ*HE*JF!3"=,@=HB%:MI-V=OM3F;&?O6OV-;!2Y!T5BE<J
MK9+.YC&C]7N%NTET%VY58M5UV\)"8QR*&_*!NX0#H()P-Y7\^[&91KV),>X*
MQL6S6-.2<MUYJUV%G&LV,0P5DI!XZ43;JJF(W;)\]A2]QA'@/QX`TF-U\K.(
MU\?+#&D,)4'1`CDJ.O,.&0L_:_O#/%)@YU?D>]].S@O;]?7H-+F.=RI6Z^,W
MC-ICMS]L;OW\^?(DE+14>@P:-3+E4;O8TQ2(#W$'O.KR0I?7H!38)\C>WNR%
MC6@L4ZLT^8CV<@O'R=V>V6Q,*)&*-SJ%.=Q8?BKIK]X)\D(@FJ<P&*(@`#ST
M!`'TYNXWBS.VE(U[?R::!U!B@L=V:D65(!C`@D_.DL4HJ>A0$R7'/K]/0`$6
M[\U68FEG=4P=>Z@ZL[2?/5AB&-@GG;EQ/ED0BDXUF1,G<Y<.)`Y4T@+ZG$P<
M?7T`O6)[5N+9UJ[)9.QMAR@P3_XCB:BH^RV:<M<<S63$ZS<`,BUC$Y-$1`HE
M$52`//J/05]SKY):I4<C%P3KY1);8C-B[QS$FB*TZ32JT'+ME`07;S$TD"YE
MQCU^0=`D":2':(&6*;TZ#^,Y_P`KTLV;V`*?J77B*H@X_1D@ZOKI^GR(F!HZ
ME$9/L3=`7T$2CV\_AT$#9&\JN5==RNJIL=JC-U?()FKP\#)UVQF5Q_9544R&
M2<1;]_'*KF:)BH452E746('H(%$0'H):_P`VVRGV3WOTO0/N_P#D0_S1<?9Y
MWX_Z^_<+X7Z;]K[[W_I[]#^O;W?)^5_>>YV_W?0?_]!_CH,Z#.@K'M%MSAK4
M"K52UYC>VE)I>;>THE2BZ92K/?K'/6=XQ>R24;'5ZI1DK+.#@PCEE3&*D)2E
M(/(]!44/,1JF8O<2G[5G`2E,`$U)V`,(@8O>`@`4+D?3T_D/0?27R]:P'`1"
MB;:<`4IN1U#V$+R!B]P=O=00[A`/J`?0?3Z]!YD\NVL:GH2@[;&'CN$"ZA;"
MB(!SP(B`4#D`+^/\`Z#ZB^6K6LPB!<?;;"(?4`U#V#$0]1#U`*#R'`@(?[!Z
M#OL2^2S6[,.6:=A2&9YHJ5]R"TL;NEL<H8*RIC./L85)HTD+`WBYBZ5>&C73
MR.9/DE3I%4$_:<!X]>@OR\>-8]HZ?OG"+1DQ;+NWCMPH1%NV:MDC+.'"ZIQ*
M1)%%(@F,81`"E`1'H%7=Y-[,A[:951P+@F6EH_%;F<;5"/2AW"S!;(\VZ>?%
M6E9AV@*:I:NF41,1(QO;*W2,LIP!^@F_6Y!Q]M>Z\>-BOPMMOB)?L>Q/D,FX
MQ*3Q%C:9,5(E@K&*)=4AD,F7B&*L*",;%*J-F*W"CU1$>0`#(:N:@XOU:@Y0
M]>^X73*=R.#_`"MG.[*?=\HY2FS*F7.^L]B<F7>?`;G$"-&":@-&:":9"%_+
MW"%I'35L^:N&3UNB[9NT%6SIJY2(LW<MUR&260714`R:J*J9A*8I@$!`>!Z!
M,78;YFH^]-[D\4NEZ\&/<E!8JT@P7]I)O%/'+:47@U"$4+[D8=B]4;+(F`2*
M(J`7CT#H&P[E3*9M?KN,!9H\AZUEJ@Q$PW(J4JJT.YFXEK,0\@W,/J5[#/%D
MU"F`0'N3X^@CT"=$<ZRAI-LR"IA58WS#=Z6:N$BF,1K--&ZYDW*11#GWX>R0
MBQ^!]4CH*@//``/0.5(;"8I+A&/V"EK=$0N,WM5;VL]@?O4$VJ+-9K[YFI3B
M?_$2!5BF0*BGW**+!V%`3"`=`.YL.9_)/(_.2<VG"FDI7(D:`4'$+?\`/3=F
MJ9)PIV@9!W$4QXZ2,4AQ'A9(.0[C=Q0`HV/,;T?%-6C*7CVM155K<2W2;M(V
M):(M4Q!),J?ON#)$*9RZ4`O)U#B)S#]1Z#19QR`SQ7A_).1'RQ4$*C39^:*<
MRA4O\0TCESM2E.<0+[AW/:!0^HC].@4\\9U"4S3O'CR2GF@R#.L/;-EVPJ+E
M*H"C^&0</H%=8#"8#B6WR+)3UY#D@_B7H&/?(?F&PX/U,R==:HLLTL2[5A6H
MJ0;F,5Q&.+(\3C32"!B`)@6;(JF$OT'NXX]>@"3X8K]C*"S]D&-OCILED6\P
M42TQ],3BB7R'C\K^3>6J,:NW1N\9B8,Z;*]O/NK@F/'/'0-(=`/SR5:^OM@]
M;)*"K-65LU]K]FK$Y4TV#,KB73$)9NRFT&J@%]\C5Q#.EA6*`]IO;*80'M#@
M)Y_8B+_X+;_\[?L1]`_^,_X7]7_+_P#A_/H/_]%_CH,Z#.@%7Y)G"C7)?CE7
M3/[8DW.BQ%0!`IBA^UV0?Z3_`-10$?0>/PYY].>@LK&3KDQ"+$?NRD.!3&%-
MTN4Z:GY>0[BJE.4/X\"'(!_9P$A1D\]./!WBYQ,4`]7"P%4((A^<!`P?F`2C
MSZ<"'X?4H!W\=++@<I%'1U4S=H$,*@B7D3";CN-P;@>W@.!`0^@!]>@UV6<P
M4'!V++UF3)LZA6Z#C>LR=KMDRY[0*PB8EL9PN8I#&3!1PL(`FD7DH'5,`<AS
MZ`B]=/\`5/81S-OWJIDB<UYM]*U^P%:\I1OZK/8F$Q>9.)RC#0=7_53NND09
M1K)K&%B$W1VA'"BH)'.`*F$`Y!@'RW>3;"-!UB943#>2&63LJYXCZTM"T3$<
ME'VB_%QK9X=.PC9'["/=&/58B8BG+8J3M\9N!B.0$@'#GH!'>*#1J1WQRA>;
M?LI,KU_"^(48EH[U]QW9WD=^J;!:6KM0D!F:X0AX^:GHX(-,3R,`FJWCG*3E
M--RFNBH<I@<]J-/J=`K,)2J+68"FT^LQZ$37:M5H>/@*[!1;4O:WCHB&BF[6
M.CF2!?Z4D4R$#\`Z#H^@\3G(F0ZBARIIIE,<YSF`I"$*`F,<YC"!2E*4.1$?
M0`Z!&[:*Y'S;M1ENPP(G=DN>49.,@"))E<+.F@RX0\4BDF0I_=[R(%(0.X0_
MO_[.0=3Q-55Z-BW&]+=<"ZJ5#J5;=B4PF*+J$@6$<Y$IA]1**[<W'\N@`3YN
M<.TR.G\=9KC)R#9W2PE"F6BH&?()S=AC6:*KF#M+>,3'Y"S>']E1FZ7.42>T
MLD7G\@%$*R^,QC0\[Y9J^&M@K98;#3J$1U;\.XCEI0#XWE+:FZ37E0FH)P;V
M)A=-NF"J#94JB:A?<*8IB\@(-E-FS=FW0:-$$6K5LDF@V;-DB(-VZ"1`3210
M12*5-))(A0`I2@`%`.`Z#W=`('S,Y=)2M:&&-F3L49G+=G9Q2B2*@$<EKL+_
M`.[3"XAW%-\944$T#"'XJ`'05^\'>(#MH3+6<I%L?W)E\QH5=67`QA!C$!]P
MF5F:@E`HHK2#DJ1A`3?F1X_#H#7YGQ'4,ZXRMV*KRS%Y6[?%JQSP"=I7#53D
M%&K]FH8IO9>,G)"J)FX]!#H%(=J?'UGW5:7?3:,/)7;&S!\L_A\CU-L[46B6
M;9<%F;RQI-$1=5Z1;D#N4<%$R13\G*H3T+T%FM1?+QD_%98^FY]"4R_1$RI-
MVEJ,L17(T$F!2$*#I^X.5.TMDB@)C?+/\H>0X7$O`=`RABS+&/\`-5+BL@8S
MLL=::M+IB+=_'K%.9NX(!?D1[]#GW6,BT,;M514`#E'^("`B$B=!_])_CH,Z
M#.@$UY/%?9O?CN4[!,`;FQ`"(%`0*!L97\H]PB/H4P#Q_/Z=!+,5)F:G*<H=
MZ1R<\<\<E'DX"'</'<(>@?CZ]!)[!Y^5/L-^4Q2F0,`#ZF,?D/S?P$##Z_P]
M?PZ"0(N1[P`AB";N$`.F0PB)0,/J9+D/41$`X'TXX'^/0![\SFPN#;[J3GS0
MZ"R"\O.UV<Z`\K5!P=AJ)F<FY26F5%F4BP-8:?2VTK-5N"<=@%4=/DD6Q4QY
M$_`=!^936=,MHK-GV&U>;8-R.RSC+3JU=)0YFJ343+,UF13*2\C($?LFQ64+
M",DSNGCQ02MF[4AE3G*0.[H&Z,Z4_%[/!NM^']+J4C'T_#,"RQ-LQO3'0"TA
M7LM9Q@Z="LKG2L2WR4**MX>1#^&>'4<M')HN)0,FB004`2]`Q;X%Z!4Z)JGD
M1.M,`0<26;YX\O(.5A?2\LX:U.GI(NY>35$SE^Z42-W"8X\!W<%].@.%T&=!
M07R.;*,===;[4JS?D1OF0FCND4AFFJ0KWY<NU51E)9(@G*<J<3%&54]P/Z%>
MSUYZ`('B>U(F<UYECLXVR)5#%N(9DLH@Z?-SBVMF1T$@<1,2R.L0$W:-?652
MDGW'>":@(IJ<"J7H#C;-[HLL;6!G@["$,7,&S=K$64!0(54KMM5`5+^>QWQT
MW]U.!B8U(17,#CL[RD]>"<F`.,Q+H-'R[.SW_;272S;G#(<'(Q,Q(R7<YKE!
MC)=`R:E>H;%8QT(Y)B0_:#A(I#"(>GT`>@6#M\!D33G8MY')**QE[P]>6TK"
MOCF4(WDVL6\(]BG)CE_YF,F(X.Q;@3)F*<X&'CGH'/M?<S5S8+#M#R[5E`&,
MN,*D\6:B8IEHN7;**,)V&=`7T*[B)=JLW4#_`'D_X<=!,G0*M>:O)86C9^M8
M]8.3+,\7XVBD9)H(\IHVBX.WT^L4"\\>ZI6U8T0'_P`_'X]`;72^KQ>LNC%'
M?6I-2/:5C'4]E.Y'2;'.Y3;N&\E<Y18$$RBLX53BQ#M+P)C<``!^'06_QY>Z
M[D^B4_(U2=B]K-XK</:8-R=,R*QXV;8H/VQ7*!P!1L[137[%DC@!TE2F(8`,
M`AT'2R$>PE63J-E&321CGJ)V[QB^;I.V;MNH':HBY;+D4162.'H)3`(#T"Y/
ME3T&QSBNJ#L/A^.0J<<K/1D/=:7'D]J(]R645*VG(1`IA^(M\@@%61(7M$![
M@'\.@T?@ZM=T3RUERB-WSY?'OZ%8V-_'&.J>-CK22;0CXUTW2,(I-'4E&G<>
MYV\"L")1'GM`>@9>Z#__TW^.@SH,Z`1WE+*)KCX\^U(ZQPW,B>PJ95!-R.,;
M^'H*9@$HB`\!Z#_`/7H.'N^RV",)I@WRYF#'M#7]KO0AYRR1Q+*L;@H@DPJ4
M>=W97PJ`8!*5)F<QA^G(CT`A=L/]2EJ=K"=S5\=8[R7G"[BW<*LVSENSH%/;
MB195%-W(OY-R_LX(**D]$/@,U#D_,!@$>>@`QG_S@^2;<5=G$3F=*IX[]>[<
MO\#[A0&<U6[<_K3T/:6=,Y=FL[RO8T#-"&`3-WL<Q<";L]P"CQT'#:D^9.:T
M*(."M"V<O9XVW6DDM<LWYZAL=Q^0,DSB;AXZ!"05CHM92JX]?/79E7PR$C-S
M1&K<B:+Y("@4`*MB+*6SOF9V,U&POGK)%ZD=7E;QL0VNNPM#BS8F_?&<5J-0
ME,GZ^XM5K:S%=MK]$PC:,C57(BI(R!'#D'#@PJ$(B#A>?-%L390U5A]7J%!0
MN+JKCN+B$<0,JQ&-8V&I+VM,UFD,DVCFB220,%T5E$W0%`#K>\<YA$YA$0#-
MJ1EC+GC$RA;<:;&XWM;'#-WDFZSNU0L6^D("*L3-,S-*W0+TI$XY_&24>1)-
M^B)B.BD22.`")!(H!X8'<_4^RQB<O%;#8E,S43*H(/;M!Q3I(#$`_:NQE';-
MZ@H4!]0,F`@("'X=!`66?)A@2HIJP>'PG=DLCN2BC$4_#\8\LK87AQ$J9IB>
M9-UF3%D0`$QCH@X-P'':'/(`,.2U;S3M5?$=B/(;D&,U_P`8D72;05,D)M*`
MDRQ9/\62L5QH_<JMZ^D\(CWNE@,O(N``?4H\"4.PV'\DN/\`$]6A-8M%F,35
MJXQ;M*POEY.)62K]4:*N_BR;NHL@0!24ETT>Y=>4=%,(G,H<I#*`5;H"<Z/8
M5UWQ=37K_%%UK>7L@3X-Y/*&6R33.S7"SSLD7YCIQ*R1W#N5C63MT8ZA&JAR
M^OJ?N4`3=!=V2DHZ&CWLM+OV<7%QS99[(24BY19,6+-N0RKAT\=N#IH-FZ"9
M1,<YS`4H!R(]`LYYEY?!-WM.+;MC6Z5BVY!,SDX"V-JF_;S)1@FQ4EH=_)/H
ME1=--TU6.HBD!C"<J9N0#CH-!XH]W:_@B6L>&\MS2L'C2W//U!6YR10=_;ZC
M;%`30D&[Y40/\2,GB$`3&`!*FX2`1X`QS=`?.Y[F:OT6MOK1,9KH+IDRCUI`
MC."L,;.2\@":)EDVD=&1SA=PN]="4")D,!`[S!W"4.1`$\KYDI#.6S=ARK>$
M9&+@<BY=)8)HKA!=<86G.IYJBTCC+BGWG2A*NU;M_J`""(\<`!>@:4VXV`Q)
M(:-[$R&*<@TVS-F&(GE:;MJU-Q\@M'-+@9K18U-9B@L+IH10\N"*8*$+R;T^
MO04/\=>ZSC7S&=>P/M-4;YC"J11G*V+LEVNH3\?6BP$JY6DP@)J0<L4_8;-7
MCI06+@"F+["A4S`0I"CT!;W.Y6J#2(-.K[$X@",(B*XKIWN`75]L`$P]K)!X
MH^.H``/Y`3$_(<<<]`&S=K8.^>01U!Z]ZCX_M]UQTPL*$G;,CJPCR-JTS*,5
M%6\>5O*NDQ;MZ['^]\@5C@1RJ<."I@!>3`4+0K3:)T[Q0XK[EXUG<BW!XC-9
M`LC9(2(.';=$4(V%C.\H+$A81N<Q4BF_J5554X`5!#H+S]!__]1X7*NSFNF#
M6JCW,F<\3XO:I$4446O=]K-8*4B0<J"/W>2:B'9^/\.@'M,>;S1J3F7E0P'.
M9*V[O:/<5E5=5<57K-PR:I.X5"(3]%A)FO(%2(03&.JY(0I0Y$>@^YCL]Y,<
MZ-V[C">BL3@2LRZ1TFMOVXR-%UZQQ9N13^>XQC2ALEJ0[!#N*@\:HG,7Z@'0
M#A\B^M6UT_*Z4+[:;=R%G;VG:6+KI*5@.K#BN!K'R*)<'AY.,MZ;D;`]E12;
MG;%76:H"1)4W'J/0#EM7B1RAD7*]K6L.<\>X/U7@N^4;3573D+-GNS59NU!U
M+'O>1+L+88#XZ0'!RY!5$J)2]Y!$H<]`K7MU#:M8UVMR3!:<V>7V;BU)424J
MP6U!U-UFH&;H*_>&[>2D5E?W%-".$^$I0>(\Q>5BJ&^G0#HM%AL5HF'4C9YA
MW.2:2AVYG2[D'22?LF$/89>R)FJ+1,2<$*B4J8!]/KT!.?$-XTKEY+=GF&/T
MCR=?PSC]-G:LXWYJV<"G"5D78I-*ZR=@"2'ZGN"B)T&2(J%.8A5E0_(F80#]
M%>8Q#B[`6U'B;P]ABH1%$QS25-L(FNUR';-V:3=LUQEC8BKAV"!"'?2;Q4P*
M.%S]QU5!$QA]0Z`T=H7DFM;GG4.\BHZ4;1$@X8/YTYTH5DZ1:JJI.Y91,BBB
M<<W,7O6,!1$$P$>@!_XD-SMD/)_3,LY6SYC'`D9@6B9:R)A&HH0Q)2SRF09R
MBN8YG(79B6>@$(UG7'#AV=NF!5/=.HD;@O``(@2>VZNZ85F&L%ZN.'<-0<#6
M8V1GK)8Y:$AXV*AXN+;JOI*2E'BHH,VC5FV2.HH=00*0H"(\!T'6:[EUQM6,
MJ;EG7^L4=AC^[1*<W4K'`U9A`C*1"ZJK=N^05,R;/A;.O8$R1C#PHF(&+R4P
M"(3=/UFLVIJDRL\!!V)DDL#A%I.Q;&6:IK@0Q0620?H+I$5`AA#N`.>!'H.4
M_:7$12=W[9XX*F4O/=^C:R!"E.)O7G[=V@4PB/\`;Z]!T<'5J?4$5_TW7:Y6
M&[H4S.?LD5&PR+@2`()&7^"@W(J)0,/:)N>.?3H(XSMG##F#J?'S>9K%$Q->
MN5GKN.8*+?-_NSRZ6R\2*,'7JA!5]%-R\LDK.O70)IM$$5CJ%[A[>T!'H*]S
M6-\NGV]I<1`8&U[3T[)BZR/[[<WT/5E,C/,J*/6:=7AX:#+&&=I1#=D591=<
MW"1^0#GN#CH+4AB7$2O>0N,\<J=OY%"EIM:-P(\CVG`(X>!_MZ#Q-B+$/)"G
MQECD1$3$3*>FUH1Y`/S%(4T</J`?4`Z##XGQ"0Q4E,;8Y*93T(F>GUH#*?AP
M4IH_D_KT`JMK\PR5(W]T7T-QGB/`LA0MK37^\9P2?P""=BA,:8+AG=\"05AV
M$.G''935FAF[*/755$"R(``EZ`O<]3JE:H_[59JQ`6",]KV`83,0PDFA$>T"
M@FF@[;K)ID`H<`!0#CH%H-6;[8=E/*/MUJ7%:H:@(81TSML$ED++C2(DE9Z:
M"U/'YXJEQ4*K`IQA+5&MHMR5Z<3`BDHCZFX4*)@9@KM8JE3:!%52`@:ZS3(0
M/@048PBT0(4.U,3H,442CP'T$0$>@WWNI>Y[/N)^[V]WM=Y?<[?][LY[NWU^
MO'0>SH/_U6RL=>'3QCXTLLW=(K2_!=IN-AGY6SRELRI28O,%E4FYE^M)/WJ$
M[D]&V2;,RCQP8Q2I*D*GSP4```#H"+0->K]5BVL'6(.'KD*R(";.(@8QE#Q;
M1,```(UCX]!NT0(``'H0@!T&XZ`,_E^<@S<:&O#"8"--OXUPH"9`46,DCC'(
M"BQ$4N2G5.9,H_E*8HF^@CQST"%_D1\G.P?D$R/)ZGX!3L&-,`QK^2C)Z-?.
MUJ[(7./K:RZ=ANV99QH(EBL<P!&JKA1HH8S)JW2[U`56^H44Q'A"#RK9;%AS
M&,XXIV$<=58MVVEVEGXI5JK)5&-436<.8;N*0T'0IQTH@WJ\&"H+3SHR+IX*
MG"2;8.*RIB^?S9GW$6!\!8\<1:%G:PE5PUBI.-,I=HV"FG@J,+1DYRBQ]YU:
MK<T4-/R:XB<C-HX`A>U%,A2A^EUXV=*\9>._6:I:ZT(&3^;1.-FRID(K1)K)
M9,R7)H)DG9Q\J7A0\/&@4K&(:G$2M8Y(H>JAU3'#O,R."+;Z^,THE[C_`'?;
M<0,!Q$/RXVQMR;L#@@@'?P`\<ASQZ\CT$L^9#9W_`"C^-S:?+C-Q[-F-CF4H
MU'0*0JBTC<K\D:LP\>U(80$SM<'ZHI`4!/WE#@.>@71QEK)D&G6/P,^++'6;
ML\8=LI,2Y)W9W,=X?R?<J6B^I:)&U@J1K)!P,HSA'[NR93!=@#R0:J.69P*9
M)3W`)VA4C,56:7:H>3W6C%5YS/8L&;4^2/673/7RHW3,N3<EN%L@55XQF]G+
MG%S=OM<Y/RJL&";A1^T57<(+\E,N4022[`(7@S!68-IJULAA+7#$\/=]!=<[
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M=SF2\AH35;KV6+*Q;ZU4=:60L:+^NV&B*/F0$7*9"0^"W*0BWM$``#KM>MMM
MAK?F.PXSQ!G/.3%3R4[RV;6[!UMM>6[GD":UOTMUW15C,M6/$;FWRLTG`7&R
MKI+-X*;0`3,53@N7N6(BHF%P=Z)B"\:GD9U_;Z[WW*U:QC:M-MJ;]NG439<R
M1-L9:EXMI'S*3E:POY2SO'L/E`TV9R1A8060D7;TI4S+GY[!"LZ.`\F4?5KP
MB6.][-;3V#>39K;'#N7FMJNFQ>6'<52,/>Z7,^?V\O575L)6[!%-<5"'SG\R
MU<NE&QU$UG'L=Q.@]GD!R'+9`C+UD2BY2R)M%EW;CR&T3$NC>S=2<V7%N,<`
MXVA;37F\'B'70(J<*M>I.HM(>75LMEBFS.-L,@HJLHJ\$%#&`L&G#*7V7\WV
M]&QDI(NK#2M+<.XXT=QM-+'(NV/<Y-C%7_-)FYT^YJBJXG5$E#@CP(&5,4W\
M.@/=D&ZPV-Z'<\A6%=)M!4>K3]LEUUEDFZ9(^OQ;J5=\K+&(D0QD6H@7N$`[
MA#H$5J+&9)7\6DWDC'E^R)BC:CSB^4E%7%]SH=NLU#N\73LDY+>0T0^?RU9D
M8F:FZ&EC2/.\=-5%5&(?<O<,4>0'H)NV[S(MXP/)W-S>`\K9MR18J3H]3J!D
M)MEO,MXR76LC;$9[R4VQIK^C9*[.V%U6:NM4F\>,JK'QC)FW(V`ADFQ2G$1`
MY\;XN[&C==,<ZH[0Y0@]D,4WS]<['Y*>66?EIW9J"FZ_S:\12S%Q.(P<7CQ*
M520^#%HLCQ\:R;]C9NB<04*!G.@__]9_CH,Z#.@H'O\`Z=7+;^HXC98\RLRQ
M%=<.Y8892@+#)U1&XQCQPV@9JO+Q;Z(7=-2BDLTFSF`_(B!BAZ>O0"N#P@YR
M^Y6&8_??63[K;:U)4ZT2)-2ZNB[GJO,@X+,0DFJW?)&792H.U/D!Z&5[Q[A'
MH-_&^&;8>)@Y^M1^?=86E?M<)6ZW:85#4:JHQMD@*>U38UB)G&R+],DDR@VJ
M12H$4[NWM`1Y-Z]!N8WQ!;+P][@\H1.P.L$5D:L,5XZO7:,U$JS*QQ3-PT;Q
MYV[63;R*:Z9"Q[4B!!]3$2+VE$`YZ">TM*/)&AV^WO5B4."@7UUNC#>@>H#R
M,T/)@'GU_GT'6XJT.VC1V1P=G78G:>H92BL"MLF'J=2J>(&5'6=2F3(2!@9)
MQ(RR,HY.=LV:0*1B$[!_/S_$>@TWE:\<.:_)'`XWQE#["U_$>&Z)D"E98E:L
MO1S6>0NMUHDBY?PK&<<G<M4?TMWK%,HA_>"90@")>@^'&_CCSY5]R,Y[MVG/
M-#GLIY$U.CM7\81["@K,87#L=7GAI6#D87E3O=QKJ;74>/V@)I`LJ1,.1`!'
MH*>X]\#>4L;US34E>VX8(7_5_:?,VR]DNZ^-$)`F2[#FI@#6P3DC!N9$K;];
M,_=620>*J&`J1RB!@,0`$.RP?X2\]:_9ISJUQCY"<H4W37/.2G66+A@:OP16
MUQ<V">!E^LH.+OXR0*U..MA$U4G;YF11RHB"9?:`>3`$ZZS^,C.VNF9-T\_1
M^?J+*9,VGI%;I=*?I8_6;-<(1M(C4H.FPT`91PLXEJ[$QJ15E&ZGM>^^("IO
M41'H*^2?A`RLX\;E'\<T7M%!QU0)G25S+FN\#CXRTIF--3)<=EJ/KDJQ%Z`,
MTWMP:`>06%9054$$4P`Q>0`(TN'^G_S59*'Y#<61F],G6\=;RY)2R6M`,,>-
MS2,4_P#U)'31*_9;.$DE)RE1B(UL>/:1R1?8%`J7/8!1)T%@Z7XC-FL0[$9O
MSYB3<Z"AY'-&NN',(23>6P['*KQSG$U80J[5Q"E0DU4*Y5W0E4?C'M3&*JY$
MA#\%(!^@Y:I>$&V8DQIX^GV)LTU!OL?X^+/9W=3O,Y4WC.GY=J%W<N%;;"Y`
MCX[YL@SF94':BAI!%-TK[W:(_3GH-YM5X8LE[7U'-4[<=C(2+V)V9+3J?EW)
MC>FKR$-6<!T5XRDXG`&*(5=PW/"5*<DF`+3KPX(KS"JZIU4@[NT0WVVOA[R=
MMEENB7&6V698ZH&+-/LJZM8UI%+IRB+BF2.6\02F,;!DJ$D@>,_@RZ"<@"**
M:0$,6+[D"J%$0X"O--\$>R]5K_CK*OOC'S$[X\C*)XVKSO#,:&,TVD9$I1=3
M5+6TY0A):T1R:1_DS3I--XX^0<1*)R]QP]3SQJ;L:Y8AH^!=?-TYV/SSF7>L
M-F\EY0J=`=PI[C1G-BB9O),?DZ>14=-HVMUR'%8K)%PIS,&(WCTBBH)2"!@?
M(KJ_FK<?7"YZZ8ES;&8)C<HPTE5,@VY:L&LLZ>K2229'+*ND!=J6/>.0*8AU
MA4*()F$`Y^G0#ZQUX?\`-%<N_C%?7#8ZF6#&GC(BW$9C['T9C;[8WO#MW4VM
M+-:9UQ\D4V5ACHF-;*,S%*L"#HIU`.`G$>@B7-_@*LFSC#>*9S=LP@]RKM;E
M7%&7Z'D2K4PT7(84G,(HNV&/JY%%%ZF>2K+9@HD9P7E(QW:7O`03=!9-MXSM
MT'FMLU4[3Y)<FR>U<HWJE;K^?XR#-$1.,:!&2L"M:X"CU-&1.0;!<8F&%-Y-
J+B1TL93M$I"@(B!9/VXLG_=*W_\`U)^W'U1_ZD_[I?U_]7_^C^?0?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
